Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Jun 01, 2018 10:33pm
134 Views
Post# 28114612

RE:RE:RE:RE:RE:RE:RE:RE:RE:Why paying off EMD Sorono ?

RE:RE:RE:RE:RE:RE:RE:RE:RE:Why paying off EMD Sorono ?
JayjayUSA12007 wrote:
Why paying off Serono ?

1/ "as part of the amended agreement, EMD Serono will cancel all liens, hypothec and security interest over Theratechnologies’ assets."
Thera will be free of all liens on its assets, a pre-condition for any kind of merger or buyout.

2/ "As a result, this transaction is expected to be accretive to the company’s EBITDA by over US$4.5 million per year for the next four or five years,"

Furthermore, the value of the company in any kind of transactions is usually based on annual revenues, EPS or EBITDA. Since an early stage pharma rarely declares positive income, EPS would be out of the equation. So, only either revenues or EBITDA left.
Now, annual revenues sometimes does not reflect a company financial heath, especially from the buyer's perspective, EBITDA would be used in most of the case to calculate a company values.


I dont really get 1). Why do you hand over a chunk of the company to some new investors to end the serono deal when you could use cash on hand now if the merger/buyout was imminent or from some of the trogarzo revenue in the coming Q's if its further down the line. If you know you're selling the company this seems like a complex and pricey way to go about this small part of the process.

Bullboard Posts